ONCR Stock Overview
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Oncorus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.43 |
| 52 Week High | US$3.26 |
| 52 Week Low | US$0.23 |
| Beta | 2.43 |
| 1 Month Change | 53.54% |
| 3 Month Change | -25.54% |
| 1 Year Change | -85.81% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.33% |
Recent News & Updates
Recent updates
Oncorus GAAP EPS of -$0.74 misses by $0.02
Aug 04We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate
Oct 14
Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic
Jul 09Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans
May 05What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?
Feb 26Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels
Feb 02Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.
Jan 04We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate
Jan 04Oncorus reports Q3 results
Nov 11Shareholder Returns
| ONCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.7% | -0.3% | 1.7% |
| 1Y | -85.8% | 5.3% | -9.1% |
Return vs Industry: ONCR underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: ONCR underperformed the US Market which returned -12.5% over the past year.
Price Volatility
| ONCR volatility | |
|---|---|
| ONCR Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ONCR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: ONCR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 82 | Ted Ashburn | https://www.oncorus.com |
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company’s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus.
Oncorus, Inc. Fundamentals Summary
| ONCR fundamental statistics | |
|---|---|
| Market Cap | US$11.09m |
| Earnings (TTM) | -US$76.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs ONCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$76.33m |
| Earnings | -US$76.33m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.94 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 24.1% |
How did ONCR perform over the long term?
See historical performance and comparison